{"id":"W4401364054","doi":"10.1093/oncolo/oyae181.026","title":"8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial","year":2024,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Nivolumab; Ipilimumab; Sunitinib; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004593425,0.0009556928,0.00200715,0.0003995957,0.000445246,0.001260673,0.0008017696,0.001106738,0.002316047],"category_scores_gemma":[0.002514702,0.0003715978,0.003774712,0.0003829269,0.0004941711,0.000844068,0.0005564049,0.002031232,0.0003407598],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008971017,"about_ca_system_score_gemma":0.001024746,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007896929,"about_ca_topic_score_gemma":0.002050355,"domain_scores_codex":[0.9984238,0.001027306,0.00007996374,0.0002108354,0.0000990958,0.0001588842],"domain_scores_gemma":[0.997675,0.0006023791,0.0007586411,0.0002341348,0.00009920315,0.0006305935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9533376,0.003874179,0.02021725,0.0003096735,0.005677917,0.00008123318,0.00005754299,0.001021754,0.002274818,0.00006431328,0.001170983,0.01191274],"study_design_scores_gemma":[0.6059021,0.2078009,0.1563268,0.000110395,0.01777166,0.0003898145,0.0001338811,0.004936852,0.002900801,0.0006478508,0.002983988,0.00009503039],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957576,0.00205402,0.0001607449,0.0001964157,0.00006504673,0.0003100327,0.0008415902,0.00002217527,0.0005923275],"genre_scores_gemma":[0.9963405,0.0005156905,0.0002739741,0.0002206419,0.0001170884,0.0003818278,0.001551284,0.000009386294,0.0005895405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004593425,"threshold_uncertainty_score":0.02429271,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07148638069975227,"score_gpt":0.3484030131394102,"score_spread":0.2769166324396579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}